×

Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening

  • US 10,627,392 B2
  • Filed: 06/17/2015
  • Issued: 04/21/2020
  • Est. Priority Date: 06/17/2014
  • Status: Active Grant
First Claim
Patent Images

1. A method for evaluating the therapeutic efficacy of an aromatic-cationic peptide on a disease or condition characterized by mitochondrial dysfunction in a subject, comprising:

  • assaying the level of a population of activated monocytes present in a biological sample obtained from the subject; and

    comparing the level of the population of activated monocytes observed in step (a) with the level of a corresponding population of activated monocytes observed in a biological sample obtained from the subject following administration of a dose of an aromatic-cationic peptide,wherein the aromatic-cationic peptide is identified as having a therapeutic effect on the disease or condition characterized by mitochondrial dysfunction if the level of the population of activated monocytes in the biological sample following the administration of the aromatic-cationic peptide is reduced compared to the level of the population of activated monocytes observed in step (a).

View all claims
  • 4 Assignments
Timeline View
Assignment View
    ×
    ×